ATAI Life Sciences (Drug Discovery) Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
54
- Stock Symbol
-
ATAI
- Investments
-
25
- Share Price
-
$2.62
- (As of Friday Closing)
ATAI Life Sciences (Drug Discovery) General Information
Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Contact Information
Website
www.atai.comCorporate Office
- Wallstrasse 16
- 10179 Berlin
- Germany
Corporate Office
- Wallstrasse 16
- 10179 Berlin
- Germany
ATAI Life Sciences (Drug Discovery) Stock Performance
As of 11-Jul-2025, ATAI Life Sciences (Drug Discovery)’s stock price is $2.62. Its current market cap is $579M with 212M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.62 | $2.73 | $1.03 - $2.98 | $579M | 212M | 3.36M | -$0.91 |
ATAI Life Sciences (Drug Discovery) Financials Summary
As of 31-Mar-2025, ATAI Life Sciences (Drug Discovery) has a trailing 12-month revenue of $1.87M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 232,330 | 161,660 | 43,986 | 158,853 |
| Revenue | 1,868 | 308 | 314 | 233 |
| EBITDA | (145,747) | (145,586) | (38,158) | (134,639) |
| Net Income | (148,987) | (149,269) | (40,224) | (152,385) |
| Total Assets | 195,783 | 159,387 | 293,478 | 305,441 |
| Total Debt | 26,668 | 24,706 | 19,142 | 15,341 |
ATAI Life Sciences (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ATAI Life Sciences (Drug Discovery) Comparisons
Industry
Financing
Details
ATAI Life Sciences (Drug Discovery) Competitors (12)
One of ATAI Life Sciences (Drug Discovery)’s 12 competitors is Axsome Therapeutics, a Corporation company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Axsome Therapeutics | Corporation | New York, NY | ||||
| GH Research | Formerly VC-backed | Dublin, Ireland | ||||
| Intracellular Therapies | Formerly VC-backed | Bedminster, NJ | ||||
| BioXcel Therapeutics | Formerly VC-backed | New Haven, CT | ||||
| Vistagen Therapeutics | Corporation | South San Francisco, CA |
ATAI Life Sciences (Drug Discovery) Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ATAI Life Sciences (Drug Discovery) Patents
ATAI Life Sciences (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240408054-A1 | Compositions and methods for increasing exposure of r(-)-mda | Pending | 09-Jun-2023 | ||
| US-20240425470-A1 | Substituted benzofuran propyl amine modulators of monoaminergic transporters | Pending | 09-Jun-2023 | ||
| US-20240116896-A1 | Heteroatom substituted cyclic and alkyl amines as activators of serotonin receptors | Pending | 06-Sep-2022 | ||
| US-20230270714-A1 | Salvinorin compositions | Inactive | 08-Dec-2021 | ||
| EP-4408412-A1 | Compositions and methods for treating headaches | Pending | 30-Sep-2021 | A61K31/4045 |
ATAI Life Sciences (Drug Discovery) Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ATAI Life Sciences (Drug Discovery) Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ATAI Life Sciences (Drug Discovery) Investments & Acquisitions (25)
ATAI Life Sciences (Drug Discovery)’s most recent deal was a Merger/Acquisition with Beckley Psytech for . The deal was made on 03-Jun-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Beckley Psytech | 03-Jun-2025 | Merger/Acquisition | Drug Discovery | ||
| Psilera (N,N-Dimethyltryptamine Patent Portfolio) | 20-Feb-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Intelgenx Technologies | 02-Oct-2024 | Merger/Acquisition | Drug Delivery | ||
| Beckley Psytech | 03-Jan-2024 | Later Stage VC | Drug Discovery | ||
| Intelgenx Technologies | 05-Dec-2023 | PIPE | Drug Delivery |
ATAI Life Sciences (Drug Discovery) ESG
Risk Overview
Risk Rating
Updated April, 11, 2024
33.41 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,048
Rank
Percentile
Pharmaceuticals
Industry
of 914
Rank
Percentile
Pharmaceuticals
Subindustry
of 451
Rank
Percentile
ATAI Life Sciences (Drug Discovery) Exits (4)
ATAI Life Sciences (Drug Discovery)’s most recent exit was on 17-Feb-2021 from PsyProtix. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| PsyProtix | 17-Feb-2021 | Completed |
|
||
| COMPASS Pathways | 17-Apr-2020 | Completed |
|
||
| COMPASS Pathways | 20-Sep-2018 | Completed |
|
||
| COMPASS Pathways | Later Stage VC | Completed |
ATAI Life Sciences (Drug Discovery) Affiliates
Subsidiaries (6)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Atai Life Sciences Uk | London, United Kingdom | 2021 | |
| Psyber | New York, NY | 2020 | |
| Beckley Psytech | Oxford, United Kingdom | 2018 | |
| Recognify Life Sciences | Berlin, Germany | 2018 | |
| Intelgenx Technologies | Saint-Laurent, Canada | 2003 |
ATAI Life Sciences (Drug Discovery) FAQs
-
When was ATAI Life Sciences (Drug Discovery) founded?
ATAI Life Sciences (Drug Discovery) was founded in 2018.
-
Where is ATAI Life Sciences (Drug Discovery) headquartered?
ATAI Life Sciences (Drug Discovery) is headquartered in Berlin, Germany.
-
What is the size of ATAI Life Sciences (Drug Discovery)?
ATAI Life Sciences (Drug Discovery) has 54 total employees.
-
What industry is ATAI Life Sciences (Drug Discovery) in?
ATAI Life Sciences (Drug Discovery)’s primary industry is Drug Discovery.
-
Is ATAI Life Sciences (Drug Discovery) a private or public company?
ATAI Life Sciences (Drug Discovery) is a Public company.
-
What is ATAI Life Sciences (Drug Discovery)’s stock symbol?
The ticker symbol for ATAI Life Sciences (Drug Discovery) is ATAI.
-
What is the current stock price of ATAI Life Sciences (Drug Discovery)?
As of 11-Jul-2025 the stock price of ATAI Life Sciences (Drug Discovery) is $2.62.
-
What is the current market cap of ATAI Life Sciences (Drug Discovery)?
The current market capitalization of ATAI Life Sciences (Drug Discovery) is $579M.
-
What is ATAI Life Sciences (Drug Discovery)’s current revenue?
The trailing twelve month revenue for ATAI Life Sciences (Drug Discovery) is $1.87M.
-
Who are ATAI Life Sciences (Drug Discovery)’s competitors?
Axsome Therapeutics, GH Research, Intracellular Therapies, BioXcel Therapeutics, and Vistagen Therapeutics are some of the 12 competitors of ATAI Life Sciences (Drug Discovery).
-
What is ATAI Life Sciences (Drug Discovery)’s annual earnings per share (EPS)?
ATAI Life Sciences (Drug Discovery)’s EPS for 12 months was -$0.91.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
